ArticleAnnals of hematology2025
First clinical and pedigree study of rare HBB: c.316-90 A > G variant in β-globin gene in Chinese population using third-generation sequencing.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- First clinical and molecular characterization of two rare complex β-globin variants in Chinese population using third generation sequencing.Annals of hematology · 2026Article
- Current research status of third-generation sequencing technology in thalassemia detection.Frontiers in pediatrics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionβ-thalassemia is a common genetic disease mainly caused by point mutations in the β-globin gene, eliciting a high prevalence in South China. The aim of the present study is to identify a rare HBB: c.316-90 A > G variant and provide the clinical and hematological features in two unrelated Chinese families.
methodsIn this study, we collected eight subjects from two unrelated Chinese families. Conventional thalassemia gene testing was performed to investigate common α and β-thalassemia variants based on the PCR reverse dot hybridization technique. Third-generation sequencing (TGS) was utilized to examine the rare or novel HBA1, HBA2 and HBB gene variants, which will be further verified using Sanger sequencing.
resultsA rare HBB: c.316-90 A > G variant was identified in the proband of Family 1 using TGS, and exhibited remarkably low levels of hemoglobin (Hb), Hb A2, MCV and MCH. The other members in Family 1 did not have the HBB: c.316-90 A > G variant and elicited normal hematological screening results. In Family 2, the proband also carried the HBB: c.316-90 A > G variant and exhibited low levels of MCV, MCH and Hb A2, but with normal Hb value. However, pedigree analysis results revealed that the proband's mother and nephew also carried the HBB: c.316-90 A > G variant, but with normal hematological screening results.
conclusionThis study first conducts clinical and hematological analysis of the HBB: c.316-90 A > G variant in two unrelated Chinese families, which provides valuable data for genetic counseling of the corresponding individuals.
Indexed as
Identifiers
39738591What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.